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ABSTRACT 
Purpose/Objectives 
Orbital cellulitis is an infection of the orbit that can lead to rare, but life-altering 
complications. Previous studies have suggested that corticosteroids may improve recovery in 
patients with orbital cellulitis. However, no large, multicenter studies have examined the use 
of systemic corticosteroids in children with orbital cellulitis. The objectives of this current 
study are to describe systemic corticosteroid use and associated outcomes in a national cohort 
of children hospitalized with orbital cellulitis. 
 
Design/Methods 
Using the Pediatric Health Information System, we performed a retrospective cohort 
analysis of children aged 2 months to 18 years old hospitalized with orbital cellulitis from 
2007 to 2014. Propensity score matching was performed to match children with orbital 
cellulitis who did or did not receive systemic corticosteroids on relevant clinical and 
demographic factors. Post-propensity score comparisons were performed using generalized 
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linear mixed-effects or conditional logistic regression modeling to assess for differences in 
outcomes including length of stay (LOS), cost, intensive care unit (ICU) transfer, emergency 
department (ED) revisits, and hospital readmissions between children who did or did not 
receive corticosteroids. 
 
Results 
Of 2,963 children hospitalized with orbital cellulitis who met inclusion criteria, 587 
(19.8 %) received systemic corticosteroids. In the matched cohort, there were 1,072 children 
(536 pairs) representing 41 hospitals. In the matched cohort, the LOS (Adjusted Rate Ratio 
(95 % CI): 1.08 (0.95-1.22), p=0.265) were similar but the costs were higher (1.21 (1.06-
1.37), p=0.004) in children who received corticosteroids compared with those who did not 
receive corticosteroids. Although not statistically significant, we observed a trend of higher 
rates of 14- and 30-day readmissions among children receiving corticosteroids compared to 
children who did not receive corticosteroids. 
 
Conclusions 
In this large multicenter study, children with orbital cellulitis who received systemic 
corticosteroids had higher costs, but similar LOS. Additionally, we observed a trend toward 
increased rates of readmissions among children who received systemic corticosteroids. Our 
findings suggest that systemic corticosteroids may not significantly improve recovery in 
children with orbital cellulitis. Future prospective studies are needed to more fully assess the 
risks and benefits of utilizing systemic corticosteroids in the management of children with 
orbital cellulitis.
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CHAPTER 1 
INTRODUCTION 
 
Orbital cellulitis is an infection involving the orbital tissues that frequently develops 
as a complication of an acute bacterial sinusitis.1 Due to the complex anatomy of the orbit 
and its proximity to and connection with the central nervous system, delayed treatment or 
inadequate treatment of these infections can result in significant complications, including the 
development of local abscess, reduced ocular motility, vision impairment, intracranial 
extension, and even death.1–3 Consequently, orbital cellulitis infections remain of high 
concern to clinicians due to the risk of developing such severe, life-altering complications. 
At this time no large, multicenter studies or clinical practice guidelines have 
established optimal diagnostic and treatment algorithms for orbital cellulitis. A few small, 
single institution studies have suggested benefit of adjunctive corticosteroid administration in 
patients hospitalized with orbital cellulitis4–6; however, no large, multicenter studies have 
assessed the legitimacy of these findings. Consequently, further investigation is needed to 
more broadly recommend corticosteroid administration as adjunctive management of orbital 
cellulitis infections in children. 
Nationally, there is a focus on improving health care delivery and patient outcomes 
through development and implementation of evidence-based clinical guidelines that 
standardize care practices.7 This proposed study provides the opportunity to augment our 
current knowledge of adjunctive corticosteroid use in children hospitalized with orbital 
cellulitis through analysis of a large national cohort of children. The results of this current 
research study may inform future prospective investigations aimed at more fully assessing 
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the risks and benefits of systemic corticosteroid use in children hospitalized with orbital 
cellulitis. Additionally, the results of this current study may be used to inform future 
investigations aimed at evaluating the optimal timing and dosage of systemic corticosteroids 
in the management of orbital cellulitis. 
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CHAPTER 2 
REVIEW OF THE LITERAURE 
 
Background 
Orbital cellulitis is a bacterial infection that develops within the orbital tissues 
posterior to the orbital septum. Although it is not as common as other childhood infections 
(e.g., pneumonia), orbital cellulitis warrants special attention secondary to the risk for the 
development of serious complications including intracranial extension (e.g., meningitis and 
intracranial abscess), cavernous sinus thrombosis, impaired ocular motility, vision loss, and 
death.1–3 The diagnosis and timely initiation of treatment of orbital cellulitis is imperative to 
improve patient outcomes and to prevent these serious complications. 
 
Epidemiology 
Based upon weighted national estimates from the 2012 Healthcare Cost and 
Utilization Project (HCUP) National Inpatient Sample, it is estimated that orbital cellulitis 
accounts for approximately 6,400 hospitalizations per year across all ages and an estimated 
2,400 pediatric hospitalizations per year in the United States (US).8 Despite the relative 
infrequency of orbital cellulitis infections, hospitalizations for orbital cellulitis are 
responsible for estimated national costs on the scale of $42.3 million dollars per year.8 
Although orbital cellulitis infections are observed across the age continuum, these infections 
are more prevalent among pediatric patients, with a mean reported age of 7.5 years.1,9 Orbital 
cellulitis infections have also been reported with increased frequency among males and 
among patients presenting during the fall and winter seasons.1 
4 
Etiology and Pathogenesis 
Understanding the complexity of the orbit and its structural relationship to the sinuses 
is important, as orbital cellulitis frequently develops following posterior extension of an 
adjacent bacterial sinusitis.1,10 Specifically, the orbit is comprised of seven individual bones 
that became adjoined during development of the orbit, including the frontal, sphenoid, 
palatine, zygomatic, lacrimal, ethmoid, and maxillary bones. Among these seven bones, the 
ethmoid bone is of particular interest, as it lines the medial portion of the orbit, and is 
comprised of a paper-thin portion referred to as the lamina papyracea. The lamina papyracea 
is a highly-perforated portion of bone. The perforations in this bone serve an important role 
in the pathogenesis of orbital cellulitis by providing a direct connection from the sinuses to 
the orbit, allowing for bacterial translocation from an adjacent sinusitis.1,11 Due to the 
frequency of orbital cellulitis infections developing secondary to bacterial sinusitis, these 
infections have been incorporated into the Chandler Classification11, which describes the 
orbital complications of bacterial sinusitis.  
In addition to its complex skeletal structure, the orbit and orbital contents are 
supported by a unique vascular network. In particular, the orbit and orbital contents are 
supported by multiple vessels that enter the orbit through three foramina, or openings, 
located between the bones of the orbit. The location of these vessels within the orbit not only 
contributes to the pathogenesis of these infections, but also contributes to the sequelae of 
orbital cellulitis infections. Among these vessels, the complex venous network is of particular 
importance in the pathogenesis of orbital cellulitis, as its valveless network can contribute to 
stasis and retrograde spread of bacteria.1,11  
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While the majority of orbital cellulitis infections develop as a complication of acute 
bacterial sinusitis, there are other possible etiologies that are important to acknowledge. In 
particular, orbital cellulitis has been reported following trauma to the orbit, as a complication 
secondary to surgical intervention to the orbit, and as a complication secondary to other 
bacterial infections (i.e., ophthalmic, dental, otolaryngologic, skin and soft tissue).1 
Regardless of the underlying etiology, however, the definitive diagnosis and management of 
these infections are largely similar. 
Historically, a substantial proportion of orbital cellulitis infections were attributed to 
two bacterial etiologies: Haemophilus influenzae B and Streptococcus pneumoniae. 
However, with the recommendation for universal vaccination against these bacteria, we have 
seen a sharp decline in these organisms as the causative etiology.1 Presently, the vast 
majority of orbital cellulitis infections, similar to bacterial sinusitis, are polymicrobial.1 The 
most commonly isolated bacteria include streptococci (including Streptococcus anginosus, 
Group A β-hemolytic streptococci, and Streptococcus pneumoniae), Staphylococcus aureus 
species (including Methicillin-sensitive Staphylococcus aureus and Methicillin-resistant 
Staphylococcus aureus), non-typeable Haemophilus influenzae, Moraxella catarrhalis, and 
anaerobic bacteria.1,12 Irrespective of the underlying bacterial etiology, previous studies have 
demonstrated that inoculation of microbes within the orbital tissues triggers the release of a 
number of cytokines that in turn generate an inflammatory cascade that leads to the extensive 
orbital edema observed in patients with orbital cellulitis.13,14 Notably, as with other 
inflammatory states, cytokines IL-1, IL-6, and TNF have been observed in patients with 
orbital cellulitis.13,15 
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Clinical Presentation and Diagnosis 
In addition to extensive orbital edema, children with orbital cellulitis frequently 
present with proptosis, chemosis, ophthalmoplegia, and decreased visual acuity, which are 
cardinal features distinguishing an orbital cellulitis infection from a less severe preseptal 
cellulitis infection.1,9  Although these cardinal clinical features are important to recognize, 
their identification may be technically difficult to assess in children secondary to limitations 
in the ability of pediatric patients to effectively communicate symptoms (e.g., vision 
changes) and limitations in physical examination due to age and cooperativity of the child. 
As clinical diagnosis may be technically limited, and as complications from orbital 
cellulitis may not be recognized on the basis of physical examination alone, diagnostic 
imaging is frequently utilized to guide medical management and to determine the need for 
surgical intervention for this subset of infections. Additionally, as there may be clinical 
overlap with other disease processes (e.g., preseptal cellultis, allergic reactions), diagnostic 
imaging offers the advantage of assessing for post-septal infection, which may be difficult to 
determine based solely on history and physical examination. Several diagnostic imaging 
modalities are currently available to assist with the diagnosis of orbital cellulitis, including 
ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI). 
While the choice of diagnostic imaging type is dependent on provider preference and 
availability, CT imaging is the most frequently utilized modality. 
 
Management 
Orbital cellulitis infections are generally managed with a course of antibiotics with 
surgical intervention reserved for individuals with drainable abscesses or severe disease. No 
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national guidelines exist in the United States, nor have any clinical trials been conducted to 
establish optimal empiric antibiotic regimens for this subset of infections. Similarly, there 
have been no clinical trials or large, multicenter studies to guide clinicians in the initiation of 
adjunctive therapies including systemic corticosteroid administration. While there is some 
evidence to suggest that surgical intervention is necessary following the development of large 
abscesses; there is limited evidence to guide when surgical intervention is indicated in 
patients with no definitive abscess collection or failure to improve with systemic antibiotic 
therapy alone.1 
In a prior investigation of resource use in orbital cellulitis, we observed significant 
variation across hospitals in diagnostic test use, systemic corticosteroid use, and empiric 
antimicrobial use in children hospitalized with orbital cellulitis.16 Within our study, we 
observed that nearly 20% of children were exposed to systemic corticosteroids.16 
Additionally, we observed that increased hospital-level resource utilization was associated 
with increased LOS without differences in ED return visits or readmissions.16 As there are no 
specific guidelines to direct the clinician in the management of orbital cellulitis, there is also 
likely variation within and across hospitals with regards to antimicrobial duration, use of 
adjunctive therapies, and determination of need for and timing of surgical intervention. In 
other serious infections of childhood, variation in care is associated with worsened health 
outcomes and higher costs.17–19 Consequently, understanding the degree of variation and 
uncertainty that exists in the management of orbital cellulitis infections is necessary to 
effectively prioritize evidence-based guideline development to improve the quality of care 
delivered to children with these infections. 
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Corticosteroid Use in the Management of Infectious Diseases 
Corticosteroids are a diverse class of medications that have a wide variety of 
applications based on their anti-inflammatory, metabolic, anti-proliferative, and 
vasoconstrictive properties. However, in addition to their diverse therapeutic properties this 
class of medications is associated with numerous adverse effects, including neuropsychiatric 
(e.g., behavior changes, sleep disturbance), cardiovascular (e.g., hypertension), 
endocrinological (e.g., hyperglycemia, insulin resistance), musculoskeletal (e.g., 
osteoporosis, muscular wasting), ocular (e.g., retinopathy, cataract development), and 
immunosuppressive. Due to the numerous adverse effects that may be observed with this 
class of medications, clinicians frequently attempt to leverage their beneficial properties and 
limit the risk of adverse effects through administration of short-course, high-dose ‘steroid 
bursts.' However, even with a limited course of corticosteroids, children may exhibit 
behavioral changes, sleep disturbance, hypertension, and hyperglycemia. 
Although corticosteroids are not prescribed for many infectious processes due to 
concern for depression of the host’s immune response and theoretical risk of masking disease 
progression, prior research has defined a role for these medications in certain subsets of 
infections including sepsis, bacterial meningitis, severe community acquired pneumonia, 
PCP pneumonia, croup, septic arthritis, and acute bacterial sinusitis.20–25 In the setting of 
bacterial meningitis, studies have suggested that the benefit of corticosteroids is dependent 
on the infectious organism identified, with increased benefit noted in individuals with 
bacterial meningitis secondary to Streptococcus pneumoniae.22 Conversely, in the setting of 
acute bacterial sinusitis, several studies have demonstrated that the efficacy of corticosteroids 
is not dependent on a particular microorganism, but rather in its role in reducing the degree 
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of mucosal edema and nasal drainage.20,21 Clearly, corticosteroids are a diverse class of 
pharmacologic agents with a wide variety of clinical applications and mechanisms of action, 
even among individuals with underlying infectious processes. 
 
Corticosteroid Use in the Management of Orbital Cellulitis 
Over the last decade, several case reports and single institution studies from around 
the world have suggested that co-administration of corticosteroids may be beneficial in the 
management of orbital cellulitis infections. These studies have suggested that adjunctive 
corticosteroids augment pain management and time to recovery, without adversely affecting 
clinical outcomes when given to patients with orbital cellulitis.4–6 In 2005, Yen et al. 
published a study which assessed the effect of concurrent intravenous corticosteroid 
administration in the management of pediatric orbital cellulitis and subperiosteal abscess.4 In 
this benchmark study, 23 patients were identified (12 patients in the treatment group, 11 in 
the control group) based upon retrospective chart review. Outcomes analyzed in this study 
included length of hospital stay, need for surgical drainage, treatment course, and clinical 
outcomes. Although this study had several potential limitations including lack of treatment 
standardization, small sample size, and potential selection bias, this study demonstrated no 
significant adverse clinical outcomes with co-administration of corticosteroids, and 
additionally suggested a trend toward decreased length of hospital stay in the management of 
patients with orbital cellulitis and subperiosteal abscess.4 
Two subsequent studies have also provided further evidence of the potential safety 
and benefits of corticosteroid administration in patients with orbital cellulitis. The first study 
published in 2013 by Pushker et al. demonstrated that adjunctive oral corticosteroid 
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administration was associated with faster resolution of inflammation with low risk or 
worsening infection in patients hospitalized at a tertiary eye care center in India.5 This study 
was limited in its generalizability to hospitalized children in the US based on the small 
sample size (N=21), age distribution of the study population (age range, 11-59), later time of 
presentation (Mean 7.4 ± 2.8 days within the control group, and 7.9 ± 5.1 days within the 
corticosteroid group), and longer lengths of stay (Mean 18.4 ± 5.9 days within the control 
group, and 14.1 ± 3.7 days within the corticosteroid group) compared to hospitalized children 
in the US.5 The second study published in 2015 by Davies et al. sought to evaluate the 
benefit and safety of corticosteroids, and to assess whether C-reactive protein (CRP) levels 
could serve as a marker for steroid initiation.6 This study observed that children who were 
started on a 7-day course of corticosteroid when CRP levels were less than 4mg/dl had 
shorter lengths of stay (Mean 3.96 days) compared to those who did not receive 
corticosteroids (Mean 7.17 days).6 Taken together, these three studies suggest a potential 
benefit to systemic corticosteroid administration in patients with orbital cellulitis.  
The development of evidence-based practice guidelines is important to help improve 
health care delivery and reduce unnecessary medical costs. As discussed previously, no large 
clinical trials or clinical practice guidelines have defined optimal diagnostic and treatment 
algorithms for the management of orbital cellulitis. Although a few small, single institution 
studies have investigated adjunctive corticosteroid administration for orbital cellulitis, there 
are currently no large, multicenter studies that have assessed the role of adjunctive 
corticosteroids in the management of these infections. Additionally, the studies that have 
been published are limited in their application based on sample characteristics and size, lack 
of treatment standardization in some studies, and potential introduction of bias in others. 
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Given the risks of severe life-altering complications, high costs, and lack of strong 
evidence to recommend adjunctive corticosteroid use, we performed a retrospective cohort 
study to investigate corticosteroid use in children hospitalized with orbital cellulitis. The 
objectives of this current study were to describe corticosteroid use in a national cohort of 
children with orbital cellulitis and to determine the association between adjunctive 
corticosteroid use and outcomes including hospital length of stay (LOS), cost, ICU transfers, 
emergency department (ED) revisits, and hospital readmissions. The research questions we 
sought to address in our study included: 
 
1. Is there an association between adjunctive corticosteroid administration and length of 
stay (LOS) in children hospitalized with orbital cellulitis? 
2. Is there an association between adjunctive corticosteroid administration and cost in 
children hospitalized with orbital cellulitis? 
3. Is adjunctive corticosteroid administration associated with increased frequency of 
ICU transfer in children hospitalized with orbital cellulitis? 
4. Is adjunctive corticosteroid administration associated with increased frequency of 30-
day emergency department ED revisits or hospital readmissions in children 
hospitalized with orbital cellulitis? 
 
Given the benefits of corticosteroids in the management of infections such as acute bacterial 
sinusitis, and the suggested benefit in orbital cellulitis, as reported in the literature, we 
hypothesize that adjunctive treatment with corticosteroids will decrease LOS and cost in 
children hospitalized with orbital cellulitis. 
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CHAPTER 3 
METHODS AND MATERIALS 
 
Study Design and Data Source 
We performed a multicenter, retrospective cohort study utilizing the Pediatric Health 
Information System (PHIS), an administrative and billing database of health information 
from 46 tertiary care children’s hospitals across the US that are affiliated with the Children’s 
Hospital Association (Lenexa, KS). Participating hospitals electronically submit detailed 
patient data to PHIS, including patient demographics, payment information, information on 
each episode of care including, but not limited to, admission date, disposition, and 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes. The participating hospitals also submit data on resource use (e.g., 
medication use, procedures, and imaging) for individual patients during their inpatient, 
observation, and emergency department visits. Patient identifiers such as medical record 
numbers are encrypted within the PHIS database and individual patients are assigned unique 
patient identifiers allowing for tracking of individual patients across visits. The current study 
included data from a total of 42 hospitals, with 4 hospitals excluded for billing data quality 
concerns. 
 
Study Population 
Inclusion Criteria 
Using the PHIS administrative database, we identified children aged 2 months to 18 
years old admitted to a PHIS participating hospital from January 1, 2007 to December 31, 
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2014 with a principal diagnosis of orbital cellulitis (ICD-9-CM 376.01). Notably, the ICD-9-
CM diagnosis code 376.01 encompasses a range of orbital infections including periorbital 
cellulitis, orbital cellulitis, orbital abscess, and subperiosteal orbital abscess. If patients had 
multiple visits within a thirty-day period only the first hospitalization was included. 
 
Exclusion Criteria 
To identify children with orbital cellulitis who are otherwise healthy, we excluded 
patients with congenital diseases, prematurity, low birth weight, nutritional deficiencies, and 
complex chronic conditions26 (Appendix A). Children with underlying diagnoses that would 
increase the likelihood of concomitant corticosteroid administration (e.g., asthma, adrenal 
insufficiency, arthritis) were excluded for the potential for corticosteroids to be administered 
as treatment for one of these other medical diagnoses. As the ICD-9-CM diagnosis code for 
orbital cellulitis includes other orbital infections, we utilized a series of exclusion criteria to 
reduce confounding, and to reduce the number of children with periorbital (preseptal) 
disease, which is generally less severe and may be managed differently than post-septal 
infections (i.e., may be managed with oral antibiotic therapy and supportive care). Children 
with possible competing ophthalmologic diagnoses were excluded. Children with secondary 
diagnoses of intracranial abscess and trauma were excluded, as these children would be 
unlikely to undergo management for orbital cellulitis alone. Children who received antifungal 
(e.g., itraconazole) or antiviral therapy (e.g., acyclovir), as well as those who did not receive 
a systemic antibiotic administered within the first 2 days of hospitalization were excluded 
secondary to the possibility of a non-bacterial infection. Notably, as part of a previous 
investigation of orbital cellulitis, we conducted a manual chart review at Children’s Mercy 
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Kansas City to assess the accuracy of our case identification strategy.16 Of the 213 medical 
records that met inclusion criteria, our identification strategy was associated with a positive 
predictive value for orbital cellulitis with or without abscess (i.e., post-septal infection) of 
75.6%.16 
 
Measures 
Exposure/Primary Predictor 
After application of inclusion and exclusion criteria to our study population, we 
identified children who received corticosteroids. The corticosteroid treatment group was 
defined utilizing Clinical Transaction Classification (CTC) codes for enteral and parenteral 
formulations of four of the most commonly utilized systemic corticosteroids: dexamethasone, 
prednisone, prednisolone, and methylprednisolone. CTC codes are a group of PHIS derived 
codes that were developed to make billing data comparable across institutions in order to 
allow for comparisons of resource use across hospitals. Patients to be included in the control 
(i.e., non-corticosteroid use) group were identified using propensity score matching 
procedures (defined below). 
 
Outcome Measures 
The primary outcome variable of interest in our study was LOS (recorded as the 
number of days between admission and discharge). The data for LOS is available directly in 
the PHIS database and is based on hospital data derived from the date of admission and date 
of discharge. As previous research has demonstrated shortened recovery times in children 
with orbital cellulitis, we chose to examine LOS as a surrogate measure for recovery time. 
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In addition to LOS, we assessed additional outcome variables including cost, ICU 
transfers, ED revisits, and hospital readmissions in children hospitalized with orbital 
cellulitis. We chose to examine costs in order to assess the impact of corticosteroid treatment 
on health care resource use. Costs were estimated using hospital- and year- specific cost-to-
charge ratios. Costs were estimated for the index admission and for the episode of care (i.e., 
index admissions and readmission). ICU transfers, ED revisits, and hospital readmissions 
were chosen to serve as surrogate outcome measures for treatment failure and/or worsened 
clinical outcomes. ICU transfers were measured as transfers to the ICU after admission and 
were identified based on the presence of compatible CTC billing charges. ED revisits and 
hospital readmissions were assessed at 7, 14, and 30 days from the index admission 
(Appendix B). These time frames were chosen in order to best capture any subsequent visits 
that may have occurred secondary to treatment failure, treatment-associated adverse effects 
(e.g. drug allergy, reaction), or medical/surgical complication (e.g. post-surgical infection).  
Only related cause returns were considered. Related cause returns were defined a priori and 
by consensus, as a return for orbital cellulitis or as a return for reasons that could reasonably 
be attributed to management of orbital cellulitis (e.g., bacteremia, fever, and diarrhea). 
 
Covariates Used in the Propensity Score Match 
Propensity score match covariates included patient demographics (age, sex, 
race/ethnicity, payer), season, region of the US, and case mix index (CMI). Patient 
demographic and clinical characteristics were chosen based on their ability to influence the 
decision to utilize corticosteroids. We defined age groups within our study as follows: 2 
months to less than 2 years, 2-4 years, 5-9 years, 10-14 years, and 15-18 years. 
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Race/ethnicity was defined as non-Hispanic black, non-Hispanic white, Hispanic, Asian, or 
other. Payer was defined as government insurance (e.g., Medicaid), private insurance, or 
other. Season was defined based on the time of year at presentation and reported as spring, 
summer, fall, or winter. Region of the US was defined based on the location of the hospital 
within the United States and reported as Northeast, South, Midwest, and West. CMI in PHIS 
is a relative weight assigned to each discharge based on the All-Patient Refined Diagnostic 
Group (APR-DRG; 3M) assignment and ARP-DRG severity of illness (SOI) measure which 
ranges from 1 (minor) to 4 (extreme). The weights are derived by Truven Health Analytics 
(Ann Arbor, MI) from its nationally-representative pediatric database as the ratio of the 
average charge for discharges within a specific APR-DRG / SOI combination to the average 
charge for all discharges in the database. Consequently, CMI serves as an administrative 
surrogate measure for severity of illness. For simplicity of reporting and interpretation, we 
split the weights at the median into 2 groups: minor and major. 
 
Covariates Used in Post-Propensity Modeling 
Surgical intervention and antibiotic exposure were treated as covariates within post-
propensity score modeling, as these covariates were unlikely to affect the decision for 
corticosteroid initiation, but may modify the effect of corticosteroid use on the outcome. 
Surgical intervention was defined based on the presence or absence of procedural codes for 
ophthalmic or sinonasal surgical procedures. Antibiotic exposure was defined as parenteral 
antibiotics administered during the first 2 days of hospitalization (Appendix C-D). Exposure 
within the first 2 days of hospitalization was chosen in order to most closely correlate with 
empiric antibiotic choice and to minimize the influence that microbiological test results may 
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have on choice of antibiotic, which cannot be assessed within the PHIS database. The 
parenteral antibiotic category was further divided into 5 categories: 1) clindamycin alone or 
in combination with a non β-lactam antibiotic, 2) β-lactam alone or in combination, 3) 
vancomycin, daptomycin, or linezolid alone or in combination, 4) clindamycin/β-lactam 
combinations, and 5) other antibiotic. The other antibiotic category consisted of rifampin, 
tetracyclines, macrolides, trimethoprim/sulfamethoxazole, nitroimidazoles, quinolones, and 
β-lactam antibiotics not typically prescribed for the management of orbital or sinus infection. 
A child’s antibiotic regimen was categorized based upon the broadest spectrum of activity of 
the administered antibiotic agents. Categorization was reviewed and confirmed by two board-
certified pediatric infectious diseases physicians in the study group. 
 
Data Collection Procedures 
Investigators queried data from the Pediatric Health Information System (PHIS) to 
generate a study population based on the previously described inclusion and exclusion 
criteria. The data within the PHIS database is de-identified and data was recorded only for 
those records meeting all inclusion/exclusion criteria. Due to the de-identified nature of the 
data stored within PHIS and low risk for breach of confidentiality a Waiver of Informed 
Consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization 
was sought during the IRB approval. The study has been reviewed and approved by the 
Children's Mercy Kansas City Institutional Review Board (IRB) and a request to rely on 
Children’s Mercy IRB has been completed and approved by the University of Missouri-
Kansas City IRB. 
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Statistical Analysis 
From the PHIS database, we identified all children meeting the specified inclusion 
and exclusion criteria. Next, we divided children based on the presence or absence of 
exposure to corticosteroids. Prior to matching, we utilized descriptive statistics to describe 
patient demographics and our pre-specified covariates for our corticosteroid and no 
corticosteroid groups. We utilized propensity score matching to define a cohort of individuals 
who did not receive corticosteroids during their admission. Propensity score matching is a 
statistical technique that can be used to identify a comparison group by accounting for 
potential confounding from baseline covariates; this technique allows for estimation of a 
treatment effect from observational data.27 In our study, we used multivariable logistic 
regression models to generate propensity scores for exposure to corticosteroids. Variables 
used to generate our propensity scores included our covariates age, sex, race/ethnicity, payor, 
season, region of the US, and case mix index. In matching controls to cases, we utilized a 
greedy nearest neighbor algorithm and performed matching within hospitals. The model’s 
calculated C-statistic was 0.73, indicating that the model provided a good prediction of 
treatment group assignment. 
Post-propensity score comparisons among children who did or did not receive 
corticosteroids were made using generalized linear mixed-effects modeling for LOS and cost 
data or conditional logistic regression modeling for ICU transfer, ED revisit, and readmission 
data. Post-propensity score comparisons were adjusted for surgical intervention and 
antibiotic exposure. All analyses were performed with SAS version 9.2 (SAS Institute, Cary, 
NC), and p values <0.05 were considered statistically significant. 
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Sample Size Determination 
Sample estimates were determined a priori. Given the large variation in LOS 
observed in prior studies, we decided to be more conservative in our sample size estimate and 
to use a larger value of 4 days for the standard deviation of differences (which increases the 
number of patients per group required to achieve 80% power). Based on prior studies, we 
estimated that we would need to obtain aggregate information on approximately 1010 
patients (505 pairs) to detect a clinically meaningful difference in LOS, which we assume to 
be a difference in length of stay of 0.5 days. With a sample size of 505 pairs, we have 80% 
power to detect a difference in means of 0.5 days, assuming a standard deviation of 
differences of 4 and a two-sided significance level of 0.05. Assuming a mean cost of $6000 
in one group, $6500 in the second group (estimated cost derived from the mean cost for a 
hospitalization for orbital cellulitis as represented in the HCUP database8 with $500 chosen 
to represent the least economically significant difference in cost), and a standard deviation of 
$2000, we estimated that we would need to obtain aggregate information on approximately 
676 patients (338 pairs) to achieve 90% power with a two-sided significance level of 0.05. 
Thus, with a minimum of 505 pairs, our study should be sufficiently powered to examine 
both LOS and cost outcomes. 
Unplanned 30-day, all-condition readmission rates in children are low, occurring at 
an estimated rate of 6.5%.28 As readmission rates are low for the majority of pediatric 
diseases, we estimate that we would be attempting to detect a small percentage difference in 
readmission rates. Assuming a sample size of 505 pairs, we will have approximately 20% 
power to detect a difference of 1% in readmission rate based on a McNemar test using a two-
sided significance level of 0.05. Due to anticipated low rates of ICU transfers and ED revisits 
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we would similarly anticipate low power to detect differences between groups. Therefore, 
based on a priori sample size and power estimates, we anticipate that the study will be 
powered for LOS and cost, but we will need to interpret these other outcomes with caution. 
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CHAPTER 4 
RESULTS 
 
Characteristics of the Study Population 
From the PHIS database, we have been able to identify a total of 5,546 hospitalized 
children aged 2 months to 18 years admitted with a principal ICD-9-CM code for orbital 
cellulitis. Following application of our exclusion criteria, there were 2,963 hospitalizations 
for orbital cellulitis within the study period that met inclusion criteria (Figure 1). Of the 
2,963 children who met inclusion criteria, 587 (19.8%) children received systemic 
corticosteroids. The majority of children received dexamethasone (85.5%), with fewer 
children receiving prednisolone, prednisone, and methylprednisolone. 
In the pre-match study population, 74.0% of children were < 10 years of age, 63.4% 
were male, and 52.4% were non-Hispanic white (Table 1). While the distributions of sex, 
race, payer, and season did not significantly differ between children who did or did not 
receive corticosteroids, we did observe statistically significant baseline differences in the pre-
match population based on age, region of the US, and CMI. Notably, the differences in age, 
region of the US, and CMI that were observed provide further justification for the value of 
using the statistical technique of propensity score matching. 
Following propensity score matching, the overall study population was 1072 
(representing 41 of the 42 hospitals) with 536 children receiving systemic corticosteroids and 
536 not receiving corticosteroids (Table 2). Of children who were matched, 65.6% were less 
than 10 years of age, 64.1% were male, 55.8% were non- Hispanic white, 59.9% were 
hospitalized during the spring and winter, and 68.8% were located in the West or South. 
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Nearly two-thirds of the post-match cohort were categorized as having a major case-mix 
index. The c-statistic for the propensity score model was 0.73. 
 
 
 
Figure 1. Study cohort flow diagram. 
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Table 1. Demographic and clinical characteristics of the pre-match study population by 
treatment group. Data are presented as number (percent). 
 Overall No 
Steroids 
Steroids P  
N --- 2963 2376 (80.2) 587 (19.2) --- 
Age 2 mo-1 yr 604 (20.4) 550 (23.1) 54 (9.2) <0.001 
2-4 yr 671 (22.6) 570 (24.0) 101 (17.2)  
5-9 yr 918 (31.0) 720 (30.3) 198 (33.7)  
10-14 yr 619 (20.9) 422 (17.8) 197 (33.6)  
15-18 yr 151 (5.1) 114 (4.8) 37 (6.3)  
Sex Male 1880 (63.4) 1491 (62.8) 389 (66.3) 0.113 
Female 1083 (36.6) 885 (37.2) 198 (33.7)  
Race/Ethnicity Non-Hispanic White 1553 (52.4) 1225 (51.6) 328 (55.9) 0.408 
Non-Hispanic Black 651 (22.0) 535 (22.5) 116 (19.8)  
Hispanic 367 (12.4) 300 (12.6) 67 (11.4)  
Asian 61 (2.1) 50 (2.1) 11 (1.9)  
Other 331 (11.2) 266 (11.2) 65 (11.1)  
Payer Government 1339 (45.2) 1093 (46.0) 246 (41.9) 0.139 
Private 1406 (47.5) 1106 (46.5) 300 (51.1)  
Other 218 (7.4) 177 (7.4) 41 (7.0)  
Season Spring 823 (27.8) 659 (27.7) 164 (27.9) 0.571 
Summer 595 (20.1) 473 (19.9) 122 (20.8)  
Fall 637 (21.5) 523 (22.0) 114 (19.4)  
Winter 908 (30.6) 721 (30.3) 187 (31.9)  
Region of the 
United States 
Midwest 737 (24.9) 636 (26.8) 101 (17.2) <0.001 
Northeast 500 (16.9) 430 (18.1) 70 (11.9)  
South 1100 (37.1) 819 (34.5) 281 (47.9)  
West 626 (21.1) 491 (20.7) 135 (23.0)  
Case-Mix 
Index 
Minor 1755 (59.2) 1555 (65.4) 200 (34.1) <0.001 
Major 1208 (40.8) 821 (34.6) 387 (65.9)  
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Table 2. Demographic and clinical characteristics of the post-match study population by 
treatment group. Data are presented as number (percent). The c-statistic for the propensity 
score model was 0.73. 
 Overall No 
Steroids 
Steroids P 
N --- 1072 536 (50.0) 536 (50.0)  --- 
Age 2 mo-1 yr 115 (10.7) 62 (11.6) 53 (9.9) 0.381 
2-4 yr 204 (19.0) 107 (20.0) 97 (18.1)   
5-9 yr 384 (35.8) 198 (36.9) 186 (34.7)   
10-14 yr 311 (29.0) 142 (26.5) 169 (31.5)   
15-18 yr 58 (5.4) 27 (5.0) 31 (5.8)   
Sex Male 687 (64.1) 335 (62.5) 352 (65.7) 0.279 
Female 385 (35.9) 201 (37.5) 184 (34.3)   
Race/Ethnicity Non-Hispanic White 598 (55.8) 308 (57.5) 290 (54.1) 0.667 
Non-Hispanic Black 203 (18.9) 96 (17.9) 107 (20.0)   
Hispanic 133 (12.4) 69 (12.9) 64 (11.9)   
Asian 20 (1.9) 9 (1.7) 11 (2.1)   
Other 118 (11.0) 54 (10.1) 64 (11.9)   
Payer Government 473 (44.1) 237 (44.2) 236 (44.0) 0.912 
Private 540 (50.4) 268 (50.0) 272 (50.7)   
Other 59 (5.5) 31 (5.8) 28 (5.2)   
Season Spring 321 (29.9) 167 (31.2) 154 (28.7) 0.820 
Summer 210 (19.6) 104 (19.4) 106 (19.8)   
Fall 220 (20.5) 110 (20.5) 110 (20.5)   
Winter 321 (29.9) 155 (28.9) 166 (31.0)   
Region of the 
United States 
Midwest 194 (18.1) 97 (18.1) 97 (18.1) 1.000 
Northeast 140 (13.1) 70 (13.1) 70 (13.1)   
South 478 (44.6) 239 (44.6) 239 (44.6)   
West 260 (24.3) 130 (24.3) 130 (24.3)   
Case-Mix 
Index 
Minor 393 (36.7) 202 (37.7) 191 (35.6) 0.486 
Major 679 (63.3) 334 (62.3) 345 (64.4)   
 
Corticosteroid Use and Outcomes 
Prior to matching, children who received corticosteroids had a statistically 
significantly different median LOS compared to children who did not receive corticosteroids 
(Table 3). Prior to matching, children who received corticosteroids also had statistically 
higher costs, increased rates of ICU transfer, increased ED revisit rates, and increased rates 
of readmissions. 
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Table 3. Outcomes in the pre-match study population by treatment group. Data are 
presented as median [interquartile range] or N (%). Differences between corticosteroid 
and no corticosteroid treatments groups are significant at P<0.05. 
 Overall 
(n = 2963) 
No Steroids 
(n = 2376) 
Steroids 
(n = 587) 
P 
Length of Stay (Days) 3 [2, 4] 3 [2, 4] 4 [3, 6] <0.001 
Index Cost ($) 5218 
[3321, 8980] 
4663 
[3076, 7639] 
9347 
[5551, 14602] 
<0.001 
Episode Cost     
      7 Day 5296 
[3349, 9185] 
4703 
[3097, 7764] 
9661 
[5653, 14921] 
<0.001 
      14 Day 5309 
[3350, 9236] 
4716 
[3100, 7783] 
9750 
[5653, 15019] 
<0.001 
      30 Day 5328 
[3359, 9298] 
4742 
[3117, 7807] 
9835 
[5653, 15024] 
<0.001 
ICU Transfer (N) 46 (1.6) 25 (1.1) 21 (3.6) <0.001 
ED Revisit     
      7 Day 45 (1.5) 30 (1.3) 15 (2.6) 0.022 
      14 Day 65 (2.2) 43 (1.8) 22 (3.7) 0.004 
      30 Day 89 (3.0) 63 (2.7) 26 (4.4) 0.024 
Readmission     
      7 Day 43 (1.5) 25 (1.1) 18 (3.1) <0.001 
      14 Day 57 (1.9) 33 (1.4) 24 (4.1) <0.001 
      30 Day 69 (2.3) 43 (1.8) 26 (4.4) <0.001 
ED= emergency department; ICU= intensive care unit 
 
In the matched cohort, the median index LOS was 4 [IQR 3, 6] days for children who 
received corticosteroids and 3 [IQR 2, 4] days for children who did not receive 
corticosteroids (Table 4). In the matched cohort, children who received corticosteroids had an 
average LOS that was not statistically different than that for children who did not receive 
corticosteroids.  In the matched cohort, the median index costs were $9315 [IQR $5614, 
$14766] for children who received corticosteroids and $5466 [IQR $3569, $9026] for 
children who did not receive corticosteroids. Children who received corticosteroids had 
average index admission costs that were 21% higher than children who did not receive 
corticosteroids (p=0.004). Episode costs that included the index admission and readmission 
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were similarly higher at 7-, 14-, and 30-days (All p<0.001). Although not statistically 
significant, children with orbital cellulitis who received corticosteroids had a trend of 
increased rates of 14- and 30-day readmissions compared to children who did not receive 
systemic corticosteroids. 
 
Table 4. Outcomes in the post-match study population by treatment group. Data are 
presented as median [interquartile range] or N (%). Post-match comparisons are presented as 
adjusted odds ratios (aOR) or adjusted rate ratios (aRR) with 95% confidence intervals (CI). 
 Overall 
(n = 1072) 
No Steroids 
(n = 536) 
Steroids 
(n = 536) 
aOR or aRR 
(95% CI) 
P 
Length of Stay 
(Days) 
4[2, 5] 3 [2, 4] 4 [3, 6] 1.08 
(0.95-1.22) 
0.265 
 
Index Cost ($) 7103 
[4314, 12093] 
5466 
[3569, 9026] 
9315 
[5614, 14766] 
1.21 
(1.06-1.37) 
0.004 
 
Episode Cost ($)      
7 Day 7318 
[4350, 12387] 
5520 
[3569, 9120] 
9690 
[5679, 15026] 
1.24 
(1.09-1.41) 
0.001 
14 Day 7347 
[4350, 12457] 
5529 
[3569, 9147] 
9741 
[5679, 15051] 
1.25 
(1.10-1.42) 
0.001 
30 Day 7364 
[4350, 12525] 
5548 
[3569, 9268] 
9792 
[5679, 15054] 
1.24 
(1.10-1.41) 
0.001 
ICU Transfer (N) 26 (2.4) 7 (1.3) 19 (3.5) 1.8 
(0.5-6.9) 
0.374 
 
ED Revisit      
      7 Day 25 (2.3) 8 (1.5) 17 (3.2) 2.4 
(0.8-7.4) 
0.124 
      14 Day 32 (3.0) 11 (2.1) 21 (3.9) 2.2 
(0.8-6.4) 
0.147 
      30 Day 37 (3.5) 14 (2.6) 23 (4.3) 2.1 
(0.8-5.9) 
0.154 
Readmission      
      7 Day 18 (1.7) 5 (0.9) 13 (2.4) 3.0 
(0.8-11.6) 
0.109 
      14 Day 25 (2.3) 6 (1.1) 19 (3.5) 3.0 
(1.0-9.1) 
0.054 
      30 Day 31 (2.9) 8 (1.5) 23 (4.3) 2.6 
(1.0-6.7) 
0.056 
ED= emergency department; ICU= intensive care unit 
27 
CHAPTER 5 
DISCUSSION 
 
In this multicenter, retrospective cohort study, we found that nearly 20% of children 
receive systemic corticosteroids in the management of orbital cellulitis. In our study, children 
receiving systemic corticosteroids in the management of orbital cellulitis had similar LOS, 
but higher costs compared to children who did not receive corticosteroids. Although not 
reaching statistical significance, we observed a trend of higher rates of 14- and 30-day 
readmissions among children receiving corticosteroids compared to children who did not 
receive corticosteroids. Taken together, our results suggest that use of adjunctive systemic 
corticosteroids in the management of orbital cellulitis may not be as beneficial as previously 
reported in the literature. 
Wide variation exists in the management of orbital cellulitis infections. Within our 
cohort, approximately 1 in 5 children received corticosteroids, with the vast majority 
receiving dexamethasone. The variation in systemic corticosteroid use across hospitals that 
we observed may reflect the absence of strong evidence for clinical benefit in treating orbital 
cellulitis infections, physician concern for the adverse effect profile of corticosteroids (i.e., 
concern for host immune suppression), or differential prescribing based on severity of illness 
or other clinical and demographic factors. Previous research of other pediatric conditions has 
demonstrated that wide variation in care is associated with higher hospitalization rates, 
prolonged LOS, and higher cost.17,18,30–32 Future investigations aimed at defining best 
practices for orbital cellulitis infections are essential to develop evidence-based guidelines 
aimed at reducing unnecessary practice variation and improving patient outcomes. 
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Previous studies have suggested that systemic corticosteroids may be safely 
administered and helpful in improving recovery time in patients with orbital cellulitis; 
however, the generalizability of these findings to all pediatric patients is limited by their 
study designs, including their evaluation at single centers within small populations of varying 
aged patients.4–6 In particular, use of corticosteroids was associated with decreased LOS in 
two studies, and with similar average LOS, but shorter median LOS in yet another study.4–6 
In our current study, we observed similar LOS among children who did or did not receive 
corticosteroids. Although prior studies have suggested that corticosteroids reduce orbital 
inflammation and consequently improve recovery times, the similar LOS observed in 
children who did or did not receive corticosteroids in our study, suggests that corticosteroids 
may not significantly impact LOS in children hospitalized with orbital cellulitis. The similar 
LOS that we observed may also reflect diminution of the effects of corticosteroid on LOS 
secondary to variability in the timing, dose, or length of corticosteroid therapy among 
patients- factors which we are unable to assess based on our current study design. Taken 
together, our findings suggest continued clinical equipoise, and they underscore the need for 
further prospective investigations aimed at describing the efficacy and safety of 
corticosteroid use in broad populations of children hospitalized with orbital cellulitis. 
Costs have previously not been examined in other investigations of corticosteroid use 
in patients hospitalized with orbital cellulitis. In our study, children receiving corticosteroids 
had adjusted costs of hospitalization (with or without readmission) that were approximately 
21-25% higher than children who did not receive corticosteroids. While some of the 
differences in cost between those who did, or did not receive corticosteroids may reflect the 
costs of corticosteroid administration itself, a portion of this difference may also relate to 
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subtle differences in study population characteristics (i.e., differences in study populations 
secondary to the contributions of unmeasured covariates). With the growing costs of health 
care, future investigations should examine if corticosteroid use in patients with orbital 
cellulitis is associated with not only a clinical benefit, but also whether widespread use 
negatively impacts the health care system (e.g., cost, readmissions). 
Although not reaching statistical significance, children receiving corticosteroids in 
our study had a trend toward increased rates of 14- and 30-day hospital readmissions 
compared to those not receiving corticosteroids. Within our study, we accounted for various 
clinical and demographic factors including case-mix index within our propensity score match 
and adjusted our models for surgical intervention and antibiotic exposure. Despite our 
attempt to control for important clinical and demographic factors within our propensity score 
match, the higher frequency of ICU transfer among patients receiving corticosteroids may 
reflect increased risk of adverse events secondary to systemic corticosteroid prescribing or 
perhaps increased severity of illness. Similarly, while we observed increased frequency of 
readmissions among children in our cohort who received corticosteroids; these findings were 
not statistically significantly different and should be interpreted with caution as the current 
study was not powered to detect differences in readmission rates. Consequently, our findings 
further highlight the need for future prospective investigations to more completely describe 
the relationship between corticosteroid use and outcomes in children hospitalized with orbital 
cellulitis. 
This study has several important limitations. First, the ICD-9-CM diagnosis code 
376.01 encompasses a range of orbital infections including periorbital cellulitis, orbital 
cellulitis, orbital abscess, and subperiosteal orbital abscess. As such, there is a risk for 
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misclassification bias. We attempted to reduce misclassification bias through exclusion of 
potentially confounding secondary diagnoses, exclusion of children who did not receive 
antibiotics within the first 2 days of hospitalization, and use of propensity score matching to 
match patients based on clinical and demographic factors. While our case definition likely 
includes both pre- and post-septal orbital infections, the use of propensity score matching and 
our c-stat of 0.73 suggests that we likely achieved a good balance of covariates across our 
exposure groups. The similarity of our study’s original cohort to previous studies9,32-34, as 
well as the PPV of 75.6% that we observed through chart review16 further supports the 
accuracy of our case identification strategy. Another limitation of this study is that the PHIS 
database contains administrative data only. Consequently, we were limited in our ability to 
assess how factors such as severity of illness and results of laboratory or microbiologic data 
may have affected clinical decision-making. We attempted to control for severity of illness in 
the propensity score by matching on CMI and controlling for surgical intervention and 
antibiotic use in post-propensity score models. Although not statistically significant, the 
observed difference in rates of ICU use between groups may reflect a true finding or 
confounding from unmeasured differences in severity of illness that were unable to be 
accounted for with our administrative dataset and statistical techniques. Finally, our results 
may not be generalizable to all pediatric patients, as our current study only included children 
hospitalized at freestanding, tertiary care children’s hospitals, which may not fully represent 
all hospitalized children in the US. 
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CHAPTER 6 
CONCLUSIONS 
 
From our large, multicenter study of children hospitalized with orbital cellulitis we 
observed that children who received systemic corticosteroids did not have shorter lengths of 
stay, but did have higher costs. In addition, there was a trend for increased readmission rates 
within 14 and 30 days. Contrary to previous studies, our findings suggest that use of systemic 
corticosteroids in children with orbital cellulitis may not improve recovery times and may be 
associated with worsened clinical outcomes. Despite the negative findings in our study, 
future prospective investigations are needed to more decisively recommend for or against 
corticosteroid use in children. Future investigations might seek to further identify the risks 
and benefits of systemic corticosteroid use, understand population characteristics that may 
predict improved outcomes with corticosteroids, and investigate the optimal timing and 
dosage of corticosteroids for children hospitalized with orbital cellulitis.
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APPENDIX A 
 
Excluded Secondary Diagnoses 
Secondary Diagnoses ICD-9-CM 
Complex Chronic Conditions Feudtner et al26 
Congenital Conditions 253, 740-759.9, 765.17, 765.27, V136-V136.9, 
V213.4-V213.5 
Corticosteroids 255-255.9, 493-493.92, 714.30-714.33759.1, 
V586.5 
Intracranial Abscess 324-324.9 
Neoplasms 140-239.9, V107-108.9, V123, V153, E933.1 
Nutritional Deficiency 260-269.9 
Ophthalmologic Conditions 077-079.98, 360-360.9, 369, 370.49, 371-
372.9, 374-375.9, 377-379.99, V124.9, V430, 
V457.8 
Infectious Conditions (e.g., viral, fungal) 052-054.9, 098.4, 114-118, V586.2 
Trauma 349.3-349.39, 733.19, 800-999, E001-E029.2, 
E800-E849.9, E879, E880-E927.9, E928.3, 
E928.8-E929.5, E960-E969, E980-E989.9, 
V125.2, V125.5, V155.1-V155.2, V155.9, 
V908.9, V541.9 
33 
APPENDIX B 
 
Indications for 30-Day Emergency Department (ED) Revisits and Readmissions 
 
Type of 
Return 
Indication for Return (ICD-9-CM) N % 
ED Revisits Inflammation or infection of the eye (360.0, 373.13, 
376.01) 
20 37.7 
Fever (780.6) 11 20.8 
Malfunction, inflammation, or infection of a device, 
implant, or graft (996.1, 999.31) 
8 15.1 
Diarrhea or dehydration (276.51, 787.91) 4 7.5 
Headache (784.0) 3 5.7 
Sinusitis (473.2) 3 5.7 
Allergic reactions (693.0, 708.0) 2 3.8 
Cellulitis and abscess of face (682.0) 2 3.8 
Readmissions Inflammation or infection of the eye (360.0, 373.13, 
374.82, 375.32, 376.01, 376.02) 
37 54.4 
Allergic reactions (693.0, 708.0) 6 8.8 
Cellulitis and abscess of face (682.0) 5 7.4 
Sinusitis (461, 473) 5 7.4 
Malfunction, inflammation, or infection of a device, 
implant, or graft (996.1, 999.31, 999.32) 
4 5.9 
Intracranial abscess, meningitis, or other intracranial 
infection (322.9, 324.0, 324.9) 
3 4.4 
Diarrhea or dehydration (276.51, 787.91) 2 2.9 
Fever (780.6) 2 2.9 
Headache or epistaxis (784.0, 784.7) 2 2.9 
Lymphadenitis (289.3) 1 1.5 
Complications of surgical procedures or medical care 
(998.31) 
1 1.5 
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APPENDIX C 
 
Antibiotic Classification Scheme 
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APPENDIX D 
 
Antibiotic Categorization Presented as Antibiotic with Clinical Transaction Code 
(CTC) 
 
Antibiotic Groups Antibiotic (CTC) 
Clindamycin Clindamycin (124143) 
Vancomycin Daptomycin (124129), Linezolid (124137), 
Vancomycin (124133) 
β-Lactam/β-Lactamase Ampicillin/Sulbactam (121231), Cefepime (122252), 
Cefotaxime (122211), Ceftaroline (122271), 
Ceftazidime (122221), Ceftizoxime (122227), 
Ceftriaxone (122231), Ertapenem (124113), Imipenem 
(124105), Meropenem (124118) 
Piperacillin/Tazobactam (121265), 
Ticarcillin/Clavulanate (121271) 
Other Antibiotic Ampicillin (121225), Azithromycin (122421), 
Aztreonam (124121), Cefazolin (122109), Cefuroxime 
(122177), Ciprofloxacin (123201), Doxycycline 
(123115), Levofloxacin (123215), Metronidazole 
(124164), Moxifloxacin (123225), Nafcillin (121247), 
Oxacillin (121251), Penicillin G (121207,121207), 
Piperacillin (121261), Rifampin (126245), 
Trimethoprim/Sulfamethoxazole (124451) 
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